Sorrento Therapeutics Inc

SRNE

$8.60

+83.3% (1 year change)

Avg closing price

Price range

Market Cap

$2.49 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$4.76 - $19.39

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $2.49 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +83.3%
52-Week High $19.39
52-Week Low $4.76
Beta 0.87
Outstanding Shares 287 Million
Avg 30 Day Volume 6.8 Million

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

News

Global Biosimilar Interleukins Market Report 2020-2030: - Major Players are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech and Sunshine Guojian Pharmaceutical

Global Biosimilar Interleukins Market Report 2020-2030: - Major Players are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech and Sunshine Guojian Pharmaceutical

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Biosimilar In...

PR Newswire PR Newswire, 4 months ago
This post was found on Twitter: whether Sorrento Therapeutics could benefit from a short squeeze – #stocks chatter

This post was found on Twitter: whether Sorrento Therapeutics could benefit from a short squeeze – #stocks chatter

This post was found on Twitter: whether Sorrento Therapeutics could benefit from a short squeeze – #stocks chatter

Mehabe Mehabe, 5 months ago
Sorrento Therapeutics Stock Could More Than Double, Says Analyst | The Motley Fool

Sorrento Therapeutics Stock Could More Than Double, Says Analyst | The Motley Fool

The company has several promising treatments in its pipeline.

The Motley Fool The Motley Fool, 5 months ago